中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2013
Turn off MathJax
Article Contents

Progress in treatment of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2013.12.004
Research funding:

 

  • Received Date: 2013-08-08
  • Published Date: 2013-12-20
  • The incidence of nonalcoholic fatty liver disease ( NAFLD) increases with the prevalence of obesity, but specific treatment for this disease is lacking. First, the possible clinical benefits from different strategies of lifestyle modification, as well as the methods for improving intervention effect and existing problems, are reviewed. Second, the indications for bariatric surgery and the main research directions are briefly presented. Finally, several promising drugs including vitamin E, farnesoid X receptor agonist, intestinal probiotics, polyunsaturated fatty acids, glucagon-like peptide-1 receptor agonist, and pentoxifylline are elaborated on. The currently acquired clinical evidence and progress in basic research suggest that lifestyle modification is the basis for treatment in all patients with NAFLD, but better schemes are needed to improve the intervention effect; bariatric surgery is one of the effective therapies for NAFLD patients with morbid obesity who have no relevant contraindications; drug treatment should be selectively applied to the population with a confirmed diagnosis of NAFLD.

     

  • loading
  • [1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J].Hepatology, 2012, 55 (6) :2005-2023.
    [2]MUSSO G, CASSADER M, ROSINA F, et al.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD) :a systematic review and meta-analysis of randomised trials[J].Diabetologia, 2012, 55 (4) :885-904.
    [3]WONG VW, CHAN RS, WONG GL, et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease:A randomized controlled trial[J].J Hepatol, 2013, 59 (3) :536-542.
    [4]CENTIS E, MOSCATIELLO S, BUGIANESI E, et al.Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease[J].J Hepatol, 2013, 58 (4) :771-777.
    [5]KEATING SE, HACKETT DA, GEORGE J, et al.Exercise and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 57 (1) :157-166.
    [6]SULLIVAN S, KIRK EP, MITTENDORFER B, et al.Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (6) :1738-1745.
    [7]NASCIMBENI F, PAIS R, BELLENTANI S, et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol, 2013, 59 (4) :859-871.
    [8]STEPHEN S, BARANOVA A, YOUNOSSI ZM.Nonalcoholic fatty liver disease and bariatric surgery[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (2) :163-171.
    [9]VERDAM FJ, SCHOUTEN R, GREVE JW, et al.An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery[J].J Obes, 2012, 2012:597871.
    [10]BELL LN, WANG J, MURALIDHARAN S, et al.Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis:a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study[J].Hepatology, 2012, 56 (4) :1311-1318.
    [11]HOOFNAGLE JH, van NATTA ML, KLEINER DE, et al.Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2013, 38 (2) :134-143.
    [12]D'ADAMO E, MARCOVECCHIO ML, GIANNINI C, et al.Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with Vitamin E[J].Free Radic Res, 2013, 47 (3) :146-153.
    [13]MUDALIAR S, HENRY RR, SANYAL AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type2 diabetes and nonalcoholic fatty liver disease[J].Gastroenterology, 2013, 145 (3) :574-582.e1.
    [14]ADORINI L, PRUZANSKI M, SHAPIRO D.Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis[J].Drug Discov Today, 2012, 17 (17-18) :988-997.
    [15]KRAJMALNIK-BROWN R, ILHAN ZE, KANG DW, et al.Effects of gut microbes on nutrient absorption and energy regulation[J].Nutr Clin Pract, 2012, 27 (2) :201-214.
    [16]PARNELL JA, RAMAN M, RIOUX KP, et al.The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance[J].Liver Int, 2012, 32 (5) :701-711.
    [17]ENDO H, NIIOKA M, KOBAYASHI N, et al.Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats:new insight into the probiotics for the gut-liver axis[J].PLoS One, 2013, 8 (5) :e63388.
    [18]ST-JULES DE, WATTERS CA, BRUNT EM, et al.Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease[J].J Pediatr Gastroenterol Nutr, 2013, Jun 30.[Epub ahead of print]
    [19]TANAKA N, SANO K, HORIUCHI A, et al.Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2008, 42 (4) :413-418.
    [20]CAPANNI M, CALELLA F, BIAGINI MR, et al.Prolonged n-3polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:a pilot study[J].Aliment Pharmacol Ther, 2006, 23 (8) :1143-1151.
    [21]PARKER HM, JOHNSON NA, BURDON CA, et al.Omega-3supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 56 (4) :944-951.
    [22]SCORLETTI E, BYRNE CD.Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease[J].Annu Rev Nutr, 2013, 33:231-248.
    [23]LPEZ-VICARIO C, GONZLEZ-PERIZ A, RIUS B, et al.Molecular interplay between Delta5/Delta6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis[J].Gut, 2013, Mar 14.[Epub ahead of print]
    [24]SAMSON SL, BAJAJ M.Potential of incretin-based therapies for non-alcoholic fatty liver disease[J].J Diabetes Complications, 2013, 27 (4) :401-406.
    [25]ZEIN CO, YERIAN LM, GOGATE P, et al.Pentoxifylline improves nonalcoholic steatohepatitis:a randomized placebo-controlled trial[J].Hepatology, 2011, 54 (5) :1610-1619.
    [26]SHARGORODSKY M, OMELCHENKO E, MATAS Z, et al.Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis:effects beyond glucose lowering?[J].Cardiovasc Diabetol, 2012, 11:61.
    [27]CHEN HP, SHIEH JJ, CHANG CC, et al.Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner:population-based and in vitro studies[J].Gut, 2013, 62 (4) :606-615.
    [28]NSEIR W, MOGRABI J, GHALI M.Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis:human studies[J].Dig Dis Sci, 2012, 57 (7) :1773-1781.
    [29]HAJIAGHAMOHAMMADI AA, ZIAEE A, OVEISI S, et al.Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease:a randomized controlled pilot study[J].Hepat Mon, 2012, 12 (8) :e6099.
    [30]LOGUERCIO C, ANDREONE P, BRISC C, et al.Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease:a randomized controlled trial[J].Free Radic Biol Med, 2012, 52 (9) :1658-1665.
    [31]SHI KQ, FAN YC, LIU WY, et al.Traditional Chinese medicines benefit to nonalcoholic fatty liver disease:a systematic review and meta-analysis[J].Mol Biol Rep, 2012, 39 (10) :9715-9722.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2909) PDF downloads(692) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return